Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy
- 28 February 2005
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 41 (3), 453-460
- https://doi.org/10.1016/j.ejca.2004.10.014
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer TreatmentJNCI Journal of the National Cancer Institute, 2003
- Chemotherapy in the management of squamous-cell carcinoma of the head and neckThe Lancet Oncology, 2001
- Potential molecular prognostic markers in head and neck squamous cell carcinomasHead & Neck, 2001
- Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM stagingCurrent Opinion in Oncology, 2000
- The cellular response to p53: the decision between life and deathOncogene, 1999
- Prognostic Value of EGFR and TGF-α in Early Laryngeal Cancer Treated With RadiotherapyThe Laryngoscope, 1996
- Docetaxel: an active drug for squamous cell carcinoma of the head and neck.Journal of Clinical Oncology, 1996
- Chemotherapy for squamous cell carcinoma of head and neck: The future is nowAnnals of Oncology, 1996
- Analysis of Complete Responders after Initial Treatment with Chemotherapy in Head and Neck CancerOtolaryngology -- Head and Neck Surgery, 1985
- Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The head and neck contracts programCancer, 1984